首页> 美国卫生研究院文献>World Journal of Gastroenterology >Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions: H. pylori infection histological types and staging
【2h】

Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions: H. pylori infection histological types and staging

机译:胃癌和其他胃黏膜病变的多种遗传学改变和细胞生物学行为:幽门螺杆菌感染组织学类型和分期

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To investigate the expression of multiple genes and the behavior of cellular biology in gastric cancer (GC) and other gastric mucosal lesions and their relations to Helicobacter pylori (H. pylori) infection, tumor staging and histological subtypes.METHODS: Three hundred and twenty-seven specimens of gastric mucosa obtained via endoscopy or surgical resection, and ABC immunohistochemical staining were used to detect the expression of p53, p16, Bcl-2 and COX-2 proteins. H. pylori was determined by rapid urea test combined with pathological staining or 14C urea breath test. Cellular image analysis was performed in 66 patients with intestinal metaplasia (IM) and/or dysplasia (Dys). In 30 of them, both cancer and the paracancerous tissues were obtained at the time of surgery. Histological pattern, tumor staging, lymph node metastasis, grading of differentiation and other clinical data were studied in the medical records.RESULTS: p16 expression of IM or Dys was significantly lower in positive H. pylori chronic atrophic gastritis (CAG) than those with negative H. pylori (CAG: 54.8% vs 88.0%, IM:34.4% vs 69.6%, Dys: 23.8% vs 53.6%, all P < 0.05), Bcl-2 or COX-2 expression of IM or Dys in positive H. pylori cases was significantly higher than that without H. pylori (Bcl-2: 68.8% vs 23.9%, 90.5% vs 60.7%; COX-2: 50.0% vs 10.8%, 61.8% vs 17.8%; all P < 0.05). The mean number of most parameters of cellular image analysis in positive H. pylori group was significantly higher than that in negative H. pylori group (Ellipser: 53 ± 14, 40 ± 12 μm, Area 1: 748 ± 572, 302 ± 202 μm2, Area-2: 3050 ± 1661, 1681 ± 1990 μm2, all P < 0.05; Ellipseb: 79 ± 23, 58 ± 15 μm, Ratio 1: 22% ± 5%, 13% ± 4%, Ratio-2: 79% ± 17%, 53% ± 20%, all P < 0.01). There was significant correlation between Bcl-2 and histologic pattern of gas tric carcinoma, and between COX-2 and tumor staging or lymph node metastasis (Bcl-2: 75.0% vs 16.7%; COX-2: 76.0% vs 20.0%, 79.2% vs 16.7%; all P < 0.05).CONCLUSION: p16, Bcl-2, and COX-2 but not p53 gene may play a role in the early genesis/progression of gastric carcinoma and are associated with H. pylori infection. p53 gene is relatively late event in gastric tumorigenesis and mainly relates to its progression. There is more cellular-biological behavior of malignant tumor in gastric mucosal lesions with H. pylori infection. Aberrant Bcl-2 protein expression appears to be preferentially associated with the intestinal type cancer. COX-2 seems to be related to tumor staging and lymph node metastasis.
机译:目的:探讨胃癌(GC)及其他胃黏膜病变中多种基因的表达及细胞生物学行为,并探讨其与幽门螺杆菌感染,肿瘤分期及组织学亚型的关系。通过内窥镜检查或手术切除获得的二十七个胃黏膜标本,以及ABC免疫组织化学染色检测p53,p16,Bcl-2和COX-2蛋白的表达。通过快速尿素测试结合病理染色或 14 C尿素呼气试验确定幽门螺杆菌。对66例肠上皮化生(IM)和/或不典型增生(Dys)的患者进行了细胞图像分析。在其中的30例中,在手术时同时获得了癌症和癌旁组织。在病历中对组织学类型,肿瘤分期,淋巴结转移,分化程度及其他临床数据进行了研究。幽门螺杆菌(CAG:54.8%vs 88.0%,IM:34.4%vs 69.6%,Dys:23.8%vs 53.6%,所有P <0.05),IM或Dys在阳性H中的Bcl-2或COX-2表达。幽门螺杆菌病例显着高于无幽门螺杆菌病例(Bcl-2:68.8%vs 23.9%,90.5%vs 60.7%; COX-2:50.0%vs 10.8%,61.8%vs 17.8%;所有 P < / em> <0.05)。阳性 H中细胞图像分析大多数参数的平均数。幽门组明显高于阴性 H组。幽门螺杆菌组(椭圆:53±14,40±12μm,区域1:748±572,302±202μm 2 ,区域2:3050±1661,1681±1990μm 2 ,所有 P <0.05; Ellipseb:79±23,58±15μm,比率1:22%±5%,13%±4%,比率2 :79%±17%,53%±20%,所有 P <0.01)。 Bcl-2与胃癌的组织学类型,COX-2与肿瘤分期或淋巴结转移有显着相关性(Bcl-2:75.0% vs 16.7%; COX-2: 76.0% vs 20.0%,79.2% vs 16.7%;所有 P <0.05)。结论:p16,Bcl-2和COX- 2而不是 p 53基因可能在胃癌的早期发生/发展中起作用,并且与 H有关。幽门螺杆菌感染。 p 53基因是胃癌发生中相对较晚的事件,主要与它的进展有关。在 H的胃黏膜病变中,恶性肿瘤具有更多的细胞生物学行为。幽门螺杆菌感染。异常的Bcl-2蛋白表达似乎优先与肠道型癌症相关。 COX-2似乎与肿瘤分期和淋巴结转移有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号